Enhertu for Breast Cancer: Uses, Dosage, and Cost

Enhertu contains the active drug fam-trastuzumab deruxtecan-nxki. It is an FDA-approved HER2-directed antibody and topoisomerase inhibitor conjugate. Commercially supplied as 100 mg vials in the market, it may also be known as trastuzumab deruxtecan, or T-DXd. Enhertu 100 mg is developed by Daiichi Sankyo and is promoted by AstraZeneca (AZ) globally.

Enhertu Uses for Breast Cancer: Enhertu is approved by the FDA for the treatment of adults with breast cancer that is either:

HER2-positive: These are tumors that grow quickly because of higher levels of a protein named  HER2 or human epidermal growth factor receptor 2. As per Breast Cancer Foundation, 15-20 % of breast cancers are HER2-positive, and these cancers tend to progress faster.

HER2-low: This newer term basically describes tumors that have HER2 but are not sufficient to be considered positive. Earlier these tumors would have been classified as HER2-negative. Now up to 60 percent of breast cancers are HER2-low.

More specifically, the medicine Enhertu injection is considered when these tumors are either metastatic (meaning it has spread from their initial location to distant body parts), or unresectable (meaning they can't be removed surgically).

Prior to starting Enhertu, patients must also have already been treated with other therapies (anti-HER2 therapy for HER2 +Ve cancer, or chemotherapy for HER2-low) for metastatic cancer, or had a recurrence within six months following completing these previous therapies.

Other Uses of Enhertu (fam-trastuzumab deruxtecan-nxki):

 Enhertu 100 mg injection may also be given to individuals who have:

• NSCLC, that has a specific mutation named HER2, which is unable to be removed with surgery or has metastasized, and has already been treated.
• HER2 +Ve gastric or gastroesophageal junction adenocarcinoma stomach cancer that has spread and has already been treated.

Enhertu Dosage & Administration:

Enhertu is typically administered intravenously (IV) through a method known as infusion therapy. It is an ADC, a type of targeted medicine, meaning it travels to the tumor and releases chemo to the cells that produce excess HER2, directly destroying the cells that cause harm to the body.  A dose of 5.4 mg/kg of body weight is typically given once every 21 days. Treatment duration may vary, with 7 months being the midrange treatment.

Enhertu Injection Cost & Availability:

Enhertu cost in India is mostly influenced due to the lack of easy access. Patients can consider several options that are cost-effective. Enhertu is a lifesaving medicinal product that is not (yet) available in India. But can be legally accessed from an experienced service provider Indian Pharma Network (IPN). We are specialized in delivering specialty medicinal products like sourcing Enhertu 100 mg injection in India.

Kindly WhatsApp/Call: +91 9310090915 or dial our TOLL-FREE Number: 1800-889-1064 to buy Enhertu Online in India and other countries where the medicine is not (yet) approved.